{"id":"oral-risperidone","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Weight gain"},{"rate":"20-30","effect":"Sedation/somnolence"},{"rate":"10-20","effect":"Extrapyramidal symptoms (tremor, rigidity, akathisia)"},{"rate":"40-50","effect":"Prolactin elevation/hyperprolactinemia"},{"rate":"5-10","effect":"Orthostatic hypotension"},{"rate":"15-25","effect":"Metabolic syndrome (dyslipidemia, hyperglycemia)"},{"rate":"5-10","effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Risperidone antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also blocks serotonin 5-HT2A receptors, which contributes to its efficacy in treating negative symptoms and mood disturbances. This dual antagonism at both dopamine and serotonin receptors distinguishes atypical antipsychotics from first-generation agents and provides a broader therapeutic profile.","oneSentence":"Risperidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:51.803Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute mania and maintenance)"},{"name":"Irritability associated with autism spectrum disorder"},{"name":"Behavioral disturbances in dementia"}]},"trialDetails":[{"nctId":"NCT07490353","phase":"PHASE1","title":"Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2025-11-01","conditions":"Depression - Major Depressive Disorder, Anhedonia","enrollment":85},{"nctId":"NCT07477301","phase":"PHASE2","title":"Supportive Psychotherapy as Adjunct to Risperidone for Cognitive Function and Inflammation in Schizophrenia","status":"COMPLETED","sponsor":"Hasanuddin University","startDate":"2024-12-01","conditions":"Schizophrenia, Cognitive Dysfunction, Inflamation","enrollment":46},{"nctId":"NCT06768944","phase":"PHASE2","title":"Subjective Experience Following Psilocybin","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2026-04","conditions":"Investigating the Importance of the Subjective Psychedelic Experience","enrollment":128},{"nctId":"NCT04624243","phase":"PHASE2","title":"Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-15","conditions":"Schizophrenia","enrollment":499},{"nctId":"NCT04105231","phase":"PHASE2","title":"Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lone Baandrup","startDate":"2021-06-01","conditions":"Dual Diagnosis","enrollment":64},{"nctId":"NCT01625897","phase":"PHASE2, PHASE3","title":"A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Schizophrenia","enrollment":125},{"nctId":"NCT01625000","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of MP-214 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Schizophrenia","enrollment":512},{"nctId":"NCT02469155","phase":"PHASE3","title":"A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2015-06","conditions":"Schizophrenia","enrollment":696},{"nctId":"NCT00539071","phase":"PHASE4","title":"High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2008-03","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":160},{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT06276361","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2023-09-26","conditions":"Schizophrenia","enrollment":58},{"nctId":"NCT02634463","phase":"PHASE1","title":"Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-11-09","conditions":"Immunoassay, Antipsychotic","enrollment":81},{"nctId":"NCT07116850","phase":"NA","title":"Adjunctive iTBS for First-Episode Schizophrenia","status":"COMPLETED","sponsor":"The First Hospital of Hebei Medical University","startDate":"2024-01-01","conditions":"Schizophrenia Disorder","enrollment":100},{"nctId":"NCT07060872","phase":"NA","title":"the Effect of Formulation on Anxiety in Autist Childre A Randomized Controlled Trial Assesses Spirulina Syrup Plus Risperidone in Children With Non-idiopathic Autism. Anxiety is Measured Using the SCAS (Parent Version) Via Daily Online Surveys for One Week and Throughout a 3-month Follow-up Period.","status":"NOT_YET_RECRUITING","sponsor":"Shahid Sadoughi University of Medical Sciences and Health Services","startDate":"2025-07-07","conditions":"Age 3 to 7 Years, Mild Autism Spectrum, no Other Illness or Disorder","enrollment":82},{"nctId":"NCT06512220","phase":"PHASE2","title":"Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2025-04-21","conditions":"Treatment Resistant Depression","enrollment":12},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT03713658","phase":"PHASE4","title":"A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-10-18","conditions":"Schizophrenia","enrollment":34},{"nctId":"NCT03666715","phase":"","title":"A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal","status":"COMPLETED","sponsor":"Janssen-Cilag Farmaceutica Ltda.","startDate":"2018-08-07","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT03629951","phase":"","title":"A Study for Schizophrenia Relapse Prediction","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-29","conditions":"Schizophrenia","enrollment":333},{"nctId":"NCT04940039","phase":"PHASE4","title":"A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2021-07-22","conditions":"Schizophrenia","enrollment":93},{"nctId":"NCT06878833","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder","status":"WITHDRAWN","sponsor":"Lyndra Inc.","startDate":"2025-04-18","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":""},{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":"Schizophrenia","enrollment":762},{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT06838104","phase":"NA","title":"Effect of Melatonin on Schizophrenic Symptoms: a Randomized Placebo-Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lahore General Hospital","startDate":"2024-12-05","conditions":"Schizophrenia Disorders, Psychotic Disorder","enrollment":76},{"nctId":"NCT04418466","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant","status":"COMPLETED","sponsor":"Delpor, Inc.","startDate":"2021-04-01","conditions":"Schizophrenia","enrollment":34},{"nctId":"NCT06218979","phase":"PHASE1","title":"KF2022#3-trial: Effect of Tea and Cola Beverage on Absorption of Risperidone Oral Solution","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2023-12-08","conditions":"Psychosis, Food-drug Interaction","enrollment":12},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT05779241","phase":"PHASE3","title":"Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005","status":"COMPLETED","sponsor":"Lyndra Inc.","startDate":"2023-04-13","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":83},{"nctId":"NCT03818256","phase":"PHASE2","title":"A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2019-12-04","conditions":"Antipsychotic-induced Weight Gain (AIWG)","enrollment":71},{"nctId":"NCT05401019","phase":"PHASE2","title":"Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD)","status":"WITHDRAWN","sponsor":"Clinical Academic Center (2CA-Braga)","startDate":"2022-06","conditions":"Obsessive-Compulsive Disorder","enrollment":""},{"nctId":"NCT03055338","phase":"PHASE2","title":"An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-08","conditions":"Schizophrenia, Acute Episode","enrollment":224},{"nctId":"NCT05402111","phase":"PHASE1","title":"A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-06-13","conditions":"Schizophrenia","enrollment":31},{"nctId":"NCT05542264","phase":"PHASE1","title":"A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-11-15","conditions":"Schizophrenia","enrollment":19},{"nctId":"NCT04524403","phase":"PHASE2","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2020-09-09","conditions":"Antipsychotic-induced Weight Gain (AIWG)","enrollment":150},{"nctId":"NCT00202007","phase":"PHASE2","title":"Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2005-02","conditions":"Schizophrenia","enrollment":240},{"nctId":"NCT04512066","phase":"PHASE2","title":"A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-09-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":287},{"nctId":"NCT06060886","phase":"PHASE4","title":"Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis","status":"UNKNOWN","sponsor":"Consorcio Centro de Investigación Biomédica en Red (CIBER)","startDate":"2023-11-01","conditions":"Schizophrenia, Treatment-resistant Schizophrenia, Side Effect","enrollment":244},{"nctId":"NCT05833399","phase":"","title":"Correlation of Genetic Variations With Clinical Response in Substance Use Disorder","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-11-28","conditions":"Substance Use Disorders, Substance Dependence","enrollment":200},{"nctId":"NCT03503318","phase":"PHASE3","title":"Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2018-04-27","conditions":"Schizophrenia","enrollment":544},{"nctId":"NCT00330551","phase":"PHASE4","title":"Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2006-03","conditions":"Schizophrenia","enrollment":126},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT03893825","phase":"PHASE3","title":"A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2019-04-17","conditions":"Schizophrenia","enrollment":336},{"nctId":"NCT00845026","phase":"PHASE2","title":"A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2009-03","conditions":"Schizophrenia","enrollment":261},{"nctId":"NCT02411526","phase":"PHASE1","title":"Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia","status":"COMPLETED","sponsor":"Zogenix, Inc.","startDate":"2015-02","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":60},{"nctId":"NCT04094207","phase":"PHASE1, PHASE2","title":"Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2019-01-01","conditions":"Schizophrenia","enrollment":80},{"nctId":"NCT01052103","phase":"PHASE2","title":"A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2010-01","conditions":"Schizophrenia","enrollment":167},{"nctId":"NCT01171937","phase":"PHASE2","title":"Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2008-09","conditions":"Autism","enrollment":41},{"nctId":"NCT00711269","phase":"PHASE3","title":"Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2008-06-27","conditions":"Schizophrenia","enrollment":460},{"nctId":"NCT01451736","phase":"PHASE4","title":"Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-10","conditions":"Schizophrenia (Recent-onset)","enrollment":146},{"nctId":"NCT05179525","phase":"PHASE1","title":"Comparative Bioavailability of Risperidone.","status":"COMPLETED","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2021-03-09","conditions":"Schizophrenia","enrollment":80},{"nctId":"NCT03527186","phase":"PHASE1","title":"Comparative Bioavailability of Risperidone","status":"COMPLETED","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2018-07-09","conditions":"Schizophrenia","enrollment":81},{"nctId":"NCT02213887","phase":"PHASE4","title":"Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2014-09","conditions":"Psychotic Disorders, Gastroesophageal Reflux","enrollment":""},{"nctId":"NCT03978832","phase":"PHASE4","title":"Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2019-06-28","conditions":"Schizophrenia","enrollment":69},{"nctId":"NCT04071639","phase":"PHASE1","title":"Symptomatic Therapy for Patients With Huntington's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-03-12","conditions":"Huntington Disease","enrollment":60},{"nctId":"NCT03565068","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-20","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT03319953","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2017-12-21","conditions":"Stable Schizophrenia","enrollment":23},{"nctId":"NCT00645372","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-07","conditions":"Schizophrenia","enrollment":242},{"nctId":"NCT00221403","phase":"PHASE3","title":"Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2004-09","conditions":"Bipolar Disorder","enrollment":46},{"nctId":"NCT02146547","phase":"PHASE4","title":"European Long-acting Antipsychotics in Schizophrenia Trial","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2015-02","conditions":"Schizophrenia","enrollment":536},{"nctId":"NCT00712270","phase":"PHASE4","title":"Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia","status":"TERMINATED","sponsor":"Kettering Health Network","startDate":"2005-04","conditions":"Schizophrenia","enrollment":21},{"nctId":"NCT03568500","phase":"PHASE4","title":"A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-05-21","conditions":"Schizophrenia, Schizoaffective Disorder, First Episode Psychosis","enrollment":44},{"nctId":"NCT01913327","phase":"PHASE4","title":"Antipsychotic Effects on Brain Function in Schizophrenia","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2013-04","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":4},{"nctId":"NCT02181803","phase":"PHASE1","title":"MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-05","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT00333177","phase":"PHASE4","title":"Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2006-03","conditions":"Schizophrenia","enrollment":92},{"nctId":"NCT02532491","phase":"PHASE4","title":"Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up","status":"UNKNOWN","sponsor":"Fundación Marques de Valdecilla","startDate":"2014-05","conditions":"Schizophrenia, Psychotic Disorders","enrollment":200},{"nctId":"NCT03230864","phase":"PHASE3","title":"Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2017-07-20","conditions":"Treatment-resistant Schizophrenia","enrollment":119},{"nctId":"NCT03883204","phase":"PHASE4","title":"Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up","status":"UNKNOWN","sponsor":"Fundación Marques de Valdecilla","startDate":"2015-01-01","conditions":"Schizophrenia, Psychotic Disorders, Psychosis","enrollment":115},{"nctId":"NCT02717195","phase":"PHASE3","title":"Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2016-04","conditions":"Schizophrenia","enrollment":1098},{"nctId":"NCT03090503","phase":"PHASE4","title":"Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up","status":"UNKNOWN","sponsor":"Fundación Marques de Valdecilla","startDate":"2014-06","conditions":"Schizophrenia, Psychotic Disorders, Psychosis","enrollment":200},{"nctId":"NCT00694707","phase":"PHASE2","title":"Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-06-30","conditions":"Schizophrenia","enrollment":732},{"nctId":"NCT00130923","phase":"PHASE4","title":"Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2005-09","conditions":"Schizophrenia, Psychotic Disorders, Substance Abuse","enrollment":95},{"nctId":"NCT02600741","phase":"","title":"Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-24","conditions":"Schizophrenia","enrollment":296},{"nctId":"NCT03790085","phase":"EARLY_PHASE1","title":"Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals","status":"UNKNOWN","sponsor":"Tianjin Medical University General Hospital","startDate":"2018-09-01","conditions":"Schizophrenia, Major Depressive Disorder, Anxiety Disorders","enrollment":2700},{"nctId":"NCT02109562","phase":"PHASE3","title":"Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2014-04","conditions":"Schizophrenia","enrollment":354},{"nctId":"NCT01677377","phase":"PHASE2","title":"Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-08","conditions":"Schizophrenia","enrollment":45},{"nctId":"NCT02875340","phase":"PHASE2","title":"A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"ValiSeek Limited","startDate":"2016-10","conditions":"Carcinoma, Non-Small-Cell Lung, Adenocarcinoma","enrollment":8},{"nctId":"NCT02307396","phase":"PHASE4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-02-01","conditions":"Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders","enrollment":21},{"nctId":"NCT00330863","phase":"PHASE4","title":"Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2006-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":357},{"nctId":"NCT00314327","phase":"PHASE4","title":"Optimizing Response in Psychosis Study","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2006-04","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":1},{"nctId":"NCT01931059","phase":"NA","title":"Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2013-07","conditions":"Imaging of the Brain and Antipsychotics, Neuronal Network Changes","enrollment":11},{"nctId":"NCT01411085","phase":"PHASE2","title":"Risperidone and Desipramine in Alcohol Use and Schizophrenia","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2011-12","conditions":"Schizophrenia, Alcoholism, Dual Diagnosis","enrollment":12},{"nctId":"NCT03220867","phase":"PHASE1","title":"Bioequivalence Study of Xian Risperdal Tablets Compared With Gurabo Risperdal Tablets Under Fasting and Fed Conditions in Chinese Healthy Participants","status":"WITHDRAWN","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2017-12-11","conditions":"Healthy","enrollment":""},{"nctId":"NCT03390712","phase":"","title":"Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection","status":"UNKNOWN","sponsor":"Réseau de Santé Vitalité Health Network","startDate":"2018-01-02","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":328},{"nctId":"NCT00799383","phase":"PHASE3","title":"Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia","status":"COMPLETED","sponsor":"Chadi A. Calarge","startDate":"2008-11","conditions":"Risperidone-induced Hyperprolactinemia","enrollment":47},{"nctId":"NCT00272597","phase":"PHASE4","title":"Risperidone LA Heathcare Resource Study","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2005-09","conditions":"Psychosis, Schizophrenia","enrollment":30},{"nctId":"NCT02462473","phase":"PHASE2","title":"A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":9},{"nctId":"NCT02964923","phase":"","title":"Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With Schizophrenia","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2016-04","conditions":"Schizophrenia","enrollment":300},{"nctId":"NCT01140620","phase":"PHASE4","title":"Effects of Ketamine and Risperidone on Cognition","status":"COMPLETED","sponsor":"University of Manchester","startDate":"2010-06","conditions":"Healthy Volunteers, Schizophrenia","enrollment":87},{"nctId":"NCT00810667","phase":"PHASE2","title":"Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2008-11","conditions":"Schizophrenia, Cognition","enrollment":124},{"nctId":"NCT01295372","phase":"PHASE3","title":"Safety and Efficacy of Zicronapine in Patients With Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2011-04","conditions":"Schizophrenia","enrollment":160},{"nctId":"NCT02019329","phase":"PHASE1","title":"A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01","conditions":"Schizophrenia","enrollment":32},{"nctId":"NCT02758067","phase":"PHASE3","title":"Comparison of the Effectiveness of Brexpiprazole With That of Risperidone","status":"WITHDRAWN","sponsor":"H. Lundbeck A/S","startDate":"2016-06","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT00439634","phase":"PHASE2","title":"Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2007-02","conditions":"Schizophrenia","enrollment":873},{"nctId":"NCT02765555","phase":"PHASE1","title":"First in Man Study of Safety, Tolerability and PK Profile of RBP-7000","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2010-03","conditions":"Schizophrenia","enrollment":12},{"nctId":"NCT00177164","phase":"PHASE3","title":"Risperdal Consta for Bipolar Disorder","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2003-11","conditions":"Bipolar I Disorder","enrollment":50},{"nctId":"NCT01670071","phase":"PHASE4","title":"A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia","status":"TERMINATED","sponsor":"Johnson & Johnson Taiwan Ltd","startDate":"2013-01","conditions":"Schizophrenia","enrollment":17},{"nctId":"NCT02573701","phase":"NA","title":"Guideline vs Usual Treatment in Schizophrenic Adolescents","status":"COMPLETED","sponsor":"Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico","startDate":"2011-10","conditions":"Schizophrenia","enrollment":91},{"nctId":"NCT02593734","phase":"PHASE4","title":"Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana","status":"COMPLETED","sponsor":"University of Ghana Medical School","startDate":"2013-07","conditions":"Schizophrenia, Mood Disorders,, Anxiety Disorder","enrollment":139},{"nctId":"NCT02087579","phase":"PHASE1","title":"Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02","conditions":"Psychotic Disorders, Schizophrenia, Bipolar Disorder","enrollment":305},{"nctId":"NCT01624675","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2012-09","conditions":"Autistic Disorder in Children and Adolescents","enrollment":39}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ANTIPSYCHOTIC DRUG LEVEL BELOW THERAPEUTIC"},{"count":1,"reaction":"HALLUCINATION, AUDITORY"},{"count":1,"reaction":"INTENTIONAL PRODUCT MISUSE"}],"_approvalHistory":[],"publicationCount":255,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["risperdal","Risperdal","Twinings English Breakfast tea","Pepsi Max beverage","placebo risperdal"],"phase":"marketed","status":"active","brandName":"Oral Risperidone","genericName":"Oral Risperidone","companyName":"Zogenix, Inc.","companyId":"zogenix-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Irritability associated with autism spectrum disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}